Warner-lambert Company

Global Alliance for Tb Drug Development

Pfizer Corporation

Warner Lambert LLC

Andrew Mark Thompson

William Alexander Denny

Gordon William Rewcastle

Alan Kraker

Alexander James Bridges

David W Fry

Robert Frederick Meyer

Brian Desmond Palmer

Howard D Showalter

Ellen Myra Dobrusin

Zhenkun Ma

Adrian Blaser

Moana Tercel

Hamish Scott Sutherland

Iveta Kmentova

Genliang Lu

Charles Z Ding

James Marino Hamby

Jeffrey Bruce Smaill

Richard John Booth

Howard Daniel Hollis Showalter

Ho Huat Lee

Mark Robert Barvian

Roy Thomas Winters

Keith D Combrink

Jiancheng Wang

Zhipei Wu

Dianjun D Chen

Minsoo Song

Lorna Helen Mitchell

Florence Oliver Joseph McCarthy

The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treatingand other microbial infections, either alone or in combination with other anti-infective treatments.

Nitroimidazooxazines and their uses in anti-tubercular therapy

The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency againstor, and for the treatment of other microbial infections.

Nitroimidazooxazine and nitroimidazooxazole analogues and their uses

The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as

Bicyclic nitroimidazole-substituted phenyl oxazolidinones

This invention relates to pyrrolocarbazole derivatives according formula I wherein R, R, R, R, R, X and Y are as defined in the specification wherein said derivatives specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1 

Inhibitors of checkpoint kinases (Wee1 and Chk1)

Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family

Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family

Described are compositions and a method of inhibiting epidermal growth factor receptor tyrosine kinase by treating, with an effective inhibiting amount, a mammal, in need thereof, a compound of Formula II:

Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle

Novel 4-substituted amino pyrido [3,2-d]pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinases are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.

Substituted pyrido[3,2-d]pyrimidines capable of inhibiting tyrosine

Novel 4-substituted amino benzothieno�3,2-d!pyrimidine and 4-substituted amino�2,3-d!pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinases are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.

Tricyclic compounds capable of inhibiting tyrosine kinases of the

Novel 4-substituted amino pyrido pyrimidine and 4-substituted amino pyrido pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinase are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.

Bicyclic compounds capable of inhibiting tyrosine kinases of the

2-Thioindoles (2-selenoindoles) and analogous 2-indolinethione (2-indolineselenone) and polysulfide (selenide) compounds, salts thereof, methods of production, intermediates in their production, pharmaceutical compositions containing said compounds, and methods for inhibiting protein kinase dependent disease in a mammal or treating aberrant cell growth in a mammal, using said compositions, are disclosed.

2-thioindoles (selenoindoles) and related disulfides (selenides) which

Growing community of inventors

Auckland, New Zealand

Andrew Mark Thompson